Thanks to a deep expertise in drug discovery and development, Pharmaleads has designed, patented and is currently developing compounds from two first-in-class chemical families of Dual ENKephalinase 1 Inhibitors (DENKIs) 2.
Pharmaleads’ DENKIs: Painkillers armed with a completely new mode of action to tackle severe pain.
These innovative compounds, PL37 and PL265, show a high potential in the treatment of severe pain. They both act by enhancing the local concentrations of enkephalins, eliciting a “physiological” analgesia devoid of the side-effects of exogenous opiates, such as morphine.
- 1. Enkephalinases are the enzymes that rapidly inactivate endogenous opioids (our body’ “natural” analgesics) ↩
- 2. See article in Nature Reviews Drug Discovery by Pharmaleads’ scientists: Roques BP, Fournié-Zaluski MC, Wurm M Inhibiting the breakdown of endogenous opioids and cannabinoids to alleviate pain. NRDD 2012 Apr; 11(4):292-310 ↩